Page 199 - Read Online

Nakamura et al. Hepatoma Res 2019;5:16 I http://dx.doi.org/10.20517/2394-5079.2019.06 Page 11 of 11

18. Bruix J, Sherman M, American Association for the Study of Liver D. Management of hepatocellular carcinoma: an update. Hepatology
2011;53:1020-2.
19. Toshimori J, Nouso K, Nakamura S, Wada N, Morimoto Y, et al. Local recurrence and complications after percutaneous radiofrequency
ablation of hepatocellular carcinoma: a retrospective cohort study focused on tumor location. Acta Med Okayama 2015;69:219-26.
20. Kim YS, Lim HK, Rhim H, Lee MW, Choi D, et al. Ten-year outcomes of percutaneous radiofrequency ablation as first-line therapy of
early hepatocellular carcinoma: analysis of prognostic factors. J Hepatol 2013;58:89-97.
21. Dohi C, Nouso K, Miyahara K, Morimoto Y, Wada N, et al. Potential of alpha-fetoprotein as a prognostic marker after curative
radiofrequency ablation of hepatocellular carcinoma. Hepatol Res 2016;46:916-23.
22. Nouso K, Kobayashi Y, Nakamura S, Kobayashi S, Takayama H, et al. Prognostic importance of fucosylated alpha-fetoprotein in
hepatocellular carcinoma patients with low alpha-fetoprotein. J Gastroenterol Hepatol 2011;26:1195-200.